Neurocrine Biosciences Inc
NASDAQ:NBIX

Watchlist Manager
Neurocrine Biosciences Inc Logo
Neurocrine Biosciences Inc
NASDAQ:NBIX
Watchlist
Price: 123.89 USD -1.29% Market Closed
Market Cap: 12.5B USD
Have any thoughts about
Neurocrine Biosciences Inc?
Write Note

Neurocrine Biosciences Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Neurocrine Biosciences Inc
Income from Continuing Operations Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Neurocrine Biosciences Inc
NASDAQ:NBIX
Income from Continuing Operations
$385.9m
CAGR 3-Years
-5%
CAGR 5-Years
79%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Income from Continuing Operations
$5.1B
CAGR 3-Years
-12%
CAGR 5-Years
9%
CAGR 10-Years
3%
Gilead Sciences Inc
NASDAQ:GILD
Income from Continuing Operations
$113m
CAGR 3-Years
-75%
CAGR 5-Years
-47%
CAGR 10-Years
-36%
Amgen Inc
NASDAQ:AMGN
Income from Continuing Operations
$4.2B
CAGR 3-Years
-9%
CAGR 5-Years
-12%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Income from Continuing Operations
-$479.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
2%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Income from Continuing Operations
$4.7B
CAGR 3-Years
-13%
CAGR 5-Years
17%
CAGR 10-Years
30%

See Also

What is Neurocrine Biosciences Inc's Income from Continuing Operations?
Income from Continuing Operations
385.9m USD

Based on the financial report for Sep 30, 2024, Neurocrine Biosciences Inc's Income from Continuing Operations amounts to 385.9m USD.

What is Neurocrine Biosciences Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
79%

Over the last year, the Income from Continuing Operations growth was 102%. The average annual Income from Continuing Operations growth rates for Neurocrine Biosciences Inc have been -5% over the past three years , 79% over the past five years .

Back to Top